NEW YORK, Oct. 6, 2015 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE-MKT: ATNM) shares closed at $1.92, up 1.59% in yesterday's session. Trading volume was light at 217,180 shares. ATNM shares gained some traction after a drop to $1.74 per share on September 29th.
Our due diligence will show investors of Actinium Pharmaceuticals, Inc. information about the ATNM technology platform they will want to read. Get our report at the link below.
Copy and paste to browser may be required.
About Actinium Pharmaceuticals
ATNM is a company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. The Company's lead radiopharmaceutical product candidate Iomab-B is designed to be used, upon approval, in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company's second product candidate, Actimab-A, is continuing its clinical development in a Phase 1/2 trial.
About Small Cap Street
We make the connection between sophisticated investors and high quality public companies. An issuer of reports written by financial analysts who provide a straightforward assessment of the profiled company and have pledged to remain free of influence when writing research reports. They include stocks traded in the NYSE, NASDAQ, and OTCBB exchanges.
Safe Harbor Statement
This press release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to anticipated revenues, expenses, earnings, operating cash flows, the outlook for markets and the demand for products. Forward-looking statements are no guarantees of future performance and are inherently subject to uncertainties and other factors which could cause actual results to differ materially from the forward-looking statements. Such statements are based upon, among other things, assumptions made by, and information currently available to, management, including management's own knowledge and assessment of the Company's industry and competition. The Company refers interested persons to its most recent Annual Report on Form 10-K and its other SEC filings for a description of additional uncertainties and factors, which may affect forward-looking statements. The company assumes no duty to update its forward-looking statements
Content is researched, written and reviewed on a best-effort basis by a 3rd party research provider. However, we are only human and may make mistakes. This report was prepared for informational purposes only. A full disclaimer can be found by viewing the full analyst report. We do not hold any positions and have not been compensated in any form for this press release and coinciding reports. For more information and services provided beyond this press release please use contact information provided below. If you notice any errors or omissions, please notify us.
SOURCE Small Cap Street